GSK (LON:GSK) Earns Buy Rating from Shore Capital

by · The Markets Daily

GSK (LON:GSK – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at Shore Capital in a research note issued to investors on Thursday,Digital Look reports.

GSK has been the subject of several other reports. Jefferies Financial Group raised their target price on shares of GSK from GBX 2,000 to GBX 2,100 and gave the company a “buy” rating in a research note on Monday, November 3rd. JPMorgan Chase & Co. raised their price target on GSK from GBX 1,400 to GBX 1,500 and gave the stock an “underweight” rating in a report on Friday, November 7th. Finally, Berenberg Bank upped their price objective on shares of GSK from GBX 1,600 to GBX 1,660 and gave the company a “hold” rating in a report on Monday, November 24th. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of GBX 1,762.

Read Our Latest Research Report on GSK

GSK Stock Up 0.1%

GSK traded up GBX 1.25 on Thursday, hitting GBX 1,902.75. The company had a trading volume of 7,630,360 shares, compared to its average volume of 6,804,678. The stock has a fifty day moving average price of GBX 1,805.21 and a 200-day moving average price of GBX 1,595.16. GSK has a 12-month low of GBX 1,242.50 and a 12-month high of GBX 1,909.73. The company has a debt-to-equity ratio of 114.64, a quick ratio of 0.73 and a current ratio of 0.81. The stock has a market capitalization of £76.76 billion, a price-to-earnings ratio of 14.31, a P/E/G ratio of 1.24 and a beta of 0.31.

GSK (LON:GSK – Get Free Report) last released its quarterly earnings results on Wednesday, October 29th. The company reported GBX 55 EPS for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. Analysts predict that GSK will post 175.980975 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Wendy Becker bought 441 shares of the business’s stock in a transaction dated Friday, December 19th. The stock was purchased at an average cost of GBX 1,809 per share, with a total value of £7,977.69. Also, insider Jonathan Symonds bought 1,650 shares of the firm’s stock in a transaction that occurred on Monday, December 22nd. The stock was purchased at an average price of GBX 1,810 per share, with a total value of £29,865. Insiders own 0.20% of the company’s stock.

About GSK

(Get Free Report)

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.

Featured Articles